Effect of Ellagic Acid Administration on Components of Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Metabolic Syndrome
Enrolment: 32 · Results not recorded
Loading the evidence…
Nutraceutical
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Metabolic Syndrome
Enrolment: 32 · Results not recorded
Follicular Lymphoma
Enrolment: 45 · Results not recorded
Healthy
Enrolment: 19 · Results not recorded
Menopause Related Conditions · Cardiovascular Risk
Enrolment: 90 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Intra-colonic TNBS-induced colitis (Crohn's disease model)
Oral ellagic acid reduced colonic injury severity and inflammation in TNBS-induced rat colitis via MAPK and NF-kB pathway modulation.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.
Model: Arsenic trioxide-induced cardiotoxicity, arsenic trioxide 5 mg/kg intraperitoneally daily for 10 days
Ellagic acid pretreatment reduced arsenic trioxide-induced changes in glutathione peroxidase and malondialdehyde, shortened QTc prolongation and lowered troponin I and creatine kinase MB, with less cardiac tissue damage.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.